1. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

HepG2 liver cells

" in MedChemExpress (MCE) Product Catalog:

48

Inhibitors & Agonists

13

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-118224

    Parasite Infection
    BPH-715 is a bisphosphonate, inhibits Plasmodium liver-stage growth, with an IC50 of 10 μM for Plasmodium exoerythrocytic forms in HepG2 cells .
    BPH-715
  • HY-169941

    Estrogen Receptor/ERR Metabolic Disease Cancer
    ERα/ERβ antagonist-1 (Compound 10) is partial antagonists of ERα and ERβ. ERα/ERβ antagonist-1 reduces ERα and ERβ activity in a dose-dependent manner in HepG2 liver cells .
    ERα/ERβ antagonist-1
  • HY-139140

    Phosphorylase Metabolic Disease
    BAY R3401 is an orally active glycogen phosphorylase inhibitor that can achieve irreversible and non-selective inhibition of hepatic glycogenolysis. BAY R3401 inhibits glycogenolysis in liver cells, with IC50 values of 27.06 and 52.83 μM in HL-7702 and HepG2 cells, respectively. BAY R3401 can be used for the research of type 2 diabetes .
    BAY R3401
  • HY-160059

    Fluorescent Dye Cancer
    JHIT2e aptamer sodium is a molecular probe based on the aptamer JHIT2 of human liver cancer cell line HepG2 cells. JHIT2e aptamer sodiu retains the ability to specifically bind HepG2 and can deliver fluorescent materials or radionuclides to tumors .
    JHIT2e aptamer sodium
  • HY-N10207

    Endogenous Metabolite Infection Cancer
    Penicitide A is a marine secondary metabolite. Penicitide A shows moderate cytotoxicity against pathogen A. brassicae and the human hepatocellular liver carcinoma (HepG2) cell line .
    Penicitide A
  • HY-172225

    Apoptosis Autophagy Ferroptosis Cancer
    [Ru(phen)2(HMPIP)](PF6)2 (Compound 6A) is an anti-tumor agent. [Ru(phen)2(HMPIP)](PF6)2 can inhibit the proliferation and migration of HepG2 liver cancer cells, and induce apoptosis, autophagy, cell cycle arrest and ferroptosis of HepG2 liver cancer cells. [Ru(phen)2(HMPIP)](PF6)2 exerts its anti-tumor activity by stimulating immune response to increase CD8+ T cells .
    [Ru(phen)2(HMPIP)](PF6)2
  • HY-120607

    Parasite Infection Cancer
    Chevalone C, a meroterpenoid fungal metabolite, shows antimalarial activity with IC50 value of 25.00 μg/mL. Chevalone C has anti-proliferative activity on colon HCT116, liver HepG2 and melanoma A375 cancer cell lines .
    Chevalone C
  • HY-113000

    Endogenous Metabolite Cardiovascular Disease
    Cetoleic acid is a long-chain monounsaturated fatty acid found in deep-sea fish. Cetoleic acid can promote the synthesis of ALA in human HepG2 cells and EPA in vitro in salmon liver cells, affecting cholesterol levels in rodents. Cetoleic acid has potential applications in cardiovascular disease research .
    Cetoleic acid
  • HY-142101

    Others Inflammation/Immunology
    3,4-Didehydroglabridin is a natural product that can be found in licorice. 3,4-Didehydroglabridin exhibits protective activities against carbon tetrachloride-induced HepG2 cells injury. 3,4-Didehydroglabridin has the potential for the research of liver injury .
    3,4-Didehydroglabridin
  • HY-N15535

    Others Cancer
    Cuneataside E is a phenylpropanoid glycoside compound found in Lespedeza cuneata. Cuneataside E exhibits hepatoprotective activity against the toxicity induced by N-acetyl-p-aminophenol (APAP) in the human hepatocellular carcinoma cell line HepG2. Cuneataside E is promising for research of liver diseases .
    Cuneataside E
  • HY-162580

    SphK Cancer
    SphK2-IN-3 (compound 12q) is a selective active sphingosine kinase-2 inhibitor. SphK2-IN-3 has anti-proliferative activity against various cancer cells, inducing G2 phase arrest and apoptosis in liver cancer cells HepG2 .
    SphK2-IN-3
  • HY-N7905

    Others Inflammation/Immunology
    Myricetin 3'-glucoside is a glycoside derivative of quercetin. Myricetin 3'-glucoside significantly prevents ethanol-induced hepatotoxicity by reducing hepatic transaminase activity and inflammatory response in HepG2 cells. Myricetin 3'-glucoside has a certain protective effect on alcohol-induced liver injury .
    Myricetin 3'-glucoside
  • HY-128135

    PPAR Inflammation/Immunology
    MHY 553 is a PPARα agonist that is effective when taken orally. MHY 553 helps alleviate liver fat accumulation by increasing fatty acid oxidation and reducing inflammation during the aging process. MHY 553 inhibits the accumulation of triglycerides induced by liver X receptor agonists in HepG2 cells. MHY 553 significantly suppresses the expression of inflammatory mRNA in aging rats .
    MHY 553
  • HY-153547

    Parasite Infection Inflammation/Immunology
    HSP90-IN-21 (5e) is an antiplasmodial agent, with IC50 values of 0.04, 0.17 and 2.91 μM against erythrocytic stage of P. falciparum (Pf3D7 and PfDd2 strains), cytotoxicity of human liver hepatocellular carcinoma cell line (HepG2), respectively .
    HSP90-IN-21
  • HY-146350

    TrxR Cancer
    TrxR-IN-4 (Compound 1b) is a potent inhibitor of TrxR. TrxR-IN-4 induces HepG2 cells apoptosis by activating the endoplasmic reticulum stress (ERS). TrxR-IN-4 improves the CCl4-induced liver damage in vivo by down-regulation of TrxR expression and inflammation level .
    TrxR-IN-4
  • HY-164799

    FXR Inflammation/Immunology
    FXR agonist 12 (Compound C7) is the orally active agonist for FXR. FXR agonist 12 down-regulates bile acid synthesis-related genes, and up-regulates bile acid transport-related genes in HepG2 cells. FXR agonist 12 improves ANIT-induced cholestasis, ameliorates the liver damage and fibrosis in mouse NASH models .
    FXR agonist 12
  • HY-172169

    PPAR Inflammation/Immunology
    PPARγ-IN-5 (Compound A3) is the inhibitor for PPARγ. PPARγ-IN-5 inhibits lipid accumulation in hepatocytes without significant cytotoxicity in HepG2 cell (400 µM). PPARγ-IN-5 can be used in research of non-alcoholic fatty liver disease .
    PPARγ-IN-5
  • HY-N3626

    Others Cancer
    Coronalolide is a natural triterpene with anticancer effects. Coronalolide exhibits a broad cytotoxic activity for human breast (BT474), gastric (KATO-3), lung (CHAGO), colon (SW-620), and liver (Hep-G2) cancer cell lines, with IC50 values of 6.59 µg/mL, 5.85 µg/mL, 5.42 µg/mL, 4.98 µg/mL, and 6.41 µg/mL, respectively .
    Coronalolide
  • HY-147552

    HIV Infection
    HIV-1 inhibitor-35 (compound 74) is a potent HIV-1 inhibitor with EC50s of 80 nM and 70 nM for LTR and CMV in HEK293 cells, respectively. HIV-1 inhibitor-35 has inhibitory activity against liver cancer cell HepG2 with a CC50 of 40 nM. HIV-1 inhibitor-35 can be used as HIV-1 latency reversing agent .
    HIV-1 inhibitor-35
  • HY-N15577

    Drug Derivative Cancer
    Antiproliferative agent-69 (Compound 1) is a prenylated kaempferol derivative found in the fresh bud’s fur of Platanus acerifolia. Antiproliferative agent-69 shows significant antiproliferative effects against human breast cancer cells (MCF-7) and human hepatocellular carcinoma cells (Hep-G2) with IC50 values of 38.2 μM and 39.5 μM, respectively. Antiproliferative agent-69 is promising for research of breast cancer and liver cancer .
    Antiproliferative agent-69
  • HY-146398

    AMPK Metabolic Disease
    AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .
    AMPK activator 6
  • HY-N0385
    Gomisin J
    3 Publications Verification

    AMPK Calcium Channel Cardiovascular Disease Metabolic Disease
    Gomisin J is a small molecular weight lignan found in Schisandra chinensis and has been demonstrated to have vasodilatory activity . Gomisin J suppresses lipid accumulation by regulating the expression of lipogenic and lipolytic enzymes and inflammatory molecules through activation of AMPK, LKB1 and Ca 2+/calmodulin-dependent protein kinase II and inhibition of fetuin-A in HepG2 cells. gomisin J has potential benefits in treating nonalcoholic fatty liver disease .
    Gomisin J
  • HY-157404

    Pim Cancer
    Pim-1/2 kinase inhibitor 2 (compound 5b) is a competitive PIM-1 and PIM-2 kinase inhibitor with IC50s of 1.31 μM and 0.67 μM, respectively. Pim-1/2 kinase inhibitor 2 shows in-vitro low cytotoxicity against normal human lung fibroblast Wi-38 cell line and potent in-vitro anticancer activity against myeloid leukaemia (NFS-60), liver (HepG-2), prostate (PC-3), and colon (Caco-2) cancer cell lines .
    Pim-1/2 kinase inhibitor 2
  • HY-159595

    LDLR PCSK9 Metabolic Disease Inflammation/Immunology
    PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .
    PCSK9-IN-29
  • HY-169431

    VEGFR Akt Caspase Bcl-2 Family Apoptosis Cancer
    VEGFR-2/AKT-IN-2 (Compound 5) is a VEGFR-2/AKT inhibitor (IC50: 0.061 μM for VEGFRin HepG2 cell). VEGFR-2/AKT-IN-2 reduces total and phosphorylated AKT as well as up-regulates BAX and Caspase-3 and down-regulates Bcl-2 in cells, thereby promoting Apoptosis. VEGFR-2/AKT-IN-2 causes cell cycle arrest in S phase. VEGFR-2/AKT-IN-2 inhibits the growth of human liver tumor cells .
    VEGFR-2/AKT-IN-2
  • HY-149523

    Apoptosis NO Synthase Caspase Inflammation/Immunology Cancer
    Anticancer agent 157 (compound 15) is a NO inhibitor (IC50=0.62 μg/mL) with anti-inflammatory and anticancer activities. Anticancer agent 157 can bind to iNOS (inducible NO synthase) and caspase 8, causing nuclear fragmentation and chromatin condensation, inducing apoptosis. Anticancer agent 157 inhibits HT29 colon cancer cells (IC50=2.45 μg/mL), Hep-G2 liver cancer cells (IC50=3.25 μg/mL), and B16-F10 murine melanoma cells (IC50=3.84 μg/mL) .
    Anticancer agent 157
  • HY-168337

    JNK Pyruvate Kinase
    SET-171 is a JNK (c-Jun N-terminal kinase) inhibitor that exhibits significant anticancer activity and lipid metabolism regulation by inhibiting liver pyruvate kinase (PKL) expression. In anticancer studies, SET-171 shows IC50 values of 8.82 μM and 2.97 μM against HepG2 and Huh7 cell lines, respectively, indicating high cytotoxicity. Additionally, in non-alcoholic fatty liver disease (NAFLD)-related studies, SET-171 significantly reduces triacylglycerol (TAG) levels and inhibits the expression of steatosis-related proteins. SET-171 holds promise for research on hepatocellular carcinoma (HCC) and NAFLD .
    SET-171
  • HY-N4314
    Scutellarein tetramethyl ether
    1 Publications Verification

    4',5,6,7-Tetramethoxyflavone

    Bacterial COX NO Synthase NF-κB Infection Inflammation/Immunology Cancer
    Scutellarein tetramethyl ether (4',5,6,7-Tetramethoxyflavone) is a bioactive compound extracted from Eupatorium odoratum. Scutellarein tetramethyl ether exhibits anti-inflammatory, antibacterial, pro-coagulant, and anti-tumor activities. Scutellarein tetramethyl ether exerts its anti-inflammatory effects by modulating the NF-κB pathway and regulates bacterial resistance through the inhibition of efflux pumps. Additionally, Scutellarein tetramethyl ether accelerates coagulation time via the endogenous coagulation pathway. Studies have shown that Scutellarein tetramethyl ether can effectively inhibit the growth of the liver cancer cell line HepG2 (IC50= 20.08 μg/mL) .
    Scutellarein tetramethyl ether
  • HY-N4314R

    Bacterial COX NO Synthase NF-κB Infection Inflammation/Immunology Cancer
    Scutellarein tetramethyl ether (Standard) is the analytical standard of Scutellarein tetramethyl ether. This product is intended for research and analytical applications. Scutellarein tetramethyl ether (4',5,6,7-Tetramethoxyflavone) is a bioactive compound extracted from Eupatorium odoratum. Scutellarein tetramethyl ether exhibits anti-inflammatory, antibacterial, pro-coagulant, and anti-tumor activities. Scutellarein tetramethyl ether exerts its anti-inflammatory effects by modulating the NF-κB pathway and regulates bacterial resistance through the inhibition of efflux pumps. Additionally, Scutellarein tetramethyl ether accelerates coagulation time via the endogenous coagulation pathway. Studies have shown that Scutellarein tetramethyl ether can effectively inhibit the growth of the liver cancer cell line HepG2 (IC50= 20.08 μg/mL) .
    Scutellarein tetramethyl ether (Standard)
  • HY-B0854

    Fungal Keap1-Nrf2 Apoptosis Lactate Dehydrogenase Cytochrome P450 Infection Metabolic Disease Cancer
    Mancozeb is a widely used fungicide that is effective against fungal diseases in most cereals, vegetables, fruits and ornamental plants. In addition, Mancozeb can cause liver damage in mice by activating the Keap1/Nrf2 signaling pathway. Mancozeb upregulates lactate dehydrogenase and cytochrome c to alter cell metabolism and induce cell death. Mancozeb has reproductive toxicity and can induce apoptosis in ovarian cells .
    Mancozeb
  • HY-146288

    LXR Metabolic Disease
    LXR agonist 2 (compound 18rr) is a potent LXR (liver X receptor) agonist. LXR agonist 2 can stabilize NCOA1 (co-activator), leading to LXR agonism .
    LXR agonist 2
  • HY-N0401A
    (Z)-Ligustilide
    4 Publications Verification

    Bacterial Estrogen Receptor/ERR FATP Infection Metabolic Disease
    (Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6 . (Z)-Ligustilide is orally active, it inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) . (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer .
    (Z)-Ligustilide
  • HY-103697A

    Toll-like Receptor (TLR) Cancer
    Gardiquimod diTFA is an imidazoline TLR7/8 agonist. Gardiquimod diTFA inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 at concentrations below 10 μM.
    Gardiquimod diTFA
  • HY-103697AR

    Toll-like Receptor (TLR) Reference Standards Cancer
    Gardiquimod (diTFA) (Standard) is the analytical standard of Gardiquimod (diTFA). This product is intended for research and analytical applications. Gardiquimod diTFA is an imidazoline TLR7/8 agonist. Gardiquimod diTFA inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 at concentrations below 10 μM.
    Gardiquimod diTFA (Standard)
  • HY-103697R

    Toll-like Receptor (TLR) Reference Standards Cancer
    Gardiquimod (Standard) is the analytical standard of Gardiquimod. This product is intended for research and analytical applications. Gardiquimod is an imidazoline TLR7/8 agonist. Gardiquimod inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 at concentrations below 10 μM.
    Gardiquimod (Standard)
  • HY-103697B

    HIV Toll-like Receptor (TLR) Infection Cancer
    Gardiquimod (hydrochloride) is an imidazoline TLR7/8 agonist. Gardiquimod (hydrochloride) inhibits HIV-1 infection of macrophages and activates peripheral blood mononuclear cells (PBMCs). Gardiquimod (hydrochloride) specifically activates TLR7 at concentrations below 10 μM .
    Gardiquimod hydrochloride
  • HY-103697

    Toll-like Receptor (TLR) Cancer
    Gardiquimod is an imidazoline TLR7/8 agonist. Gardiquimod inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 at concentrations below 10 μM.
    Gardiquimod
  • HY-172157

    HDAC AMPK Metabolic Disease
    HDAC11-IN-2 (compound B6) is a high selective Histone Deacetylase 11 (HDAC11) inhibitor. HDAC11-IN-2 inhibits HDAC11 and HDAC8 with IC50s of 51.1 ×10 -3 μM and 5 μM, respectively. HDAC11-IN-2 inhibits denovolipogenesis (DNL) and promotes fatty acid oxidation, thus mitigating hepaticlipid accumulation and pathological symptoms in MASLD mice. HDAC11-IN-2 enhances the phosphorylation of AMPKα1 at Thr172 through the inhibition of HDAC11, consequently modulating DNL and fatty acid oxidation in the liver .
    HDAC11-IN-2
  • HY-N0316
    Mollugin
    1 Publications Verification

    JAK NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc Cancer
    Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway .
    Mollugin
  • HY-N0316R

    JAK NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc Cancer
    Mollugin (Standard) is the analytical standard of Mollugin. This product is intended for research and analytical applications. Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway .
    Mollugin (Standard)
  • HY-144725

    HDAC Apoptosis Cancer
    HDAC1/6-IN-1 (compound D7) is a potent multitarget inhibitor of GLP, HDAC6 and HDAC1, with IC50 values of 1.3, 13, and 89 nM, respectively. HDAC1/6-IN-1 can inhibit the methylation and deacetylation of H3K9 on protein level. HDAC1/6-IN-1 induces cancer cell apoptosis, G0/G1 cell cycle arrest, and blocks migration and invasion .
    HDAC1/6-IN-1
  • HY-151257

    Hippo (MST) Metabolic Disease
    IHMT-MST1-58 is a potent, selective mammalian and orally active STE20-like protein 1 kinase (MST1) inhibitor with IC50 value of 23 nM. IHMT-MST1-58 can be used for the research of Type 1/2 diabetes .
    IHMT-MST1-58
  • HY-B0402R

    1-Adamantanamine (Standard); 1-Aminoadamantane (Standard)

    Influenza Virus Orthopoxvirus SARS-CoV Apoptosis CDK Bcl-2 Family Infection Neurological Disease Cancer
    Amantadine (Standard) is the analytical standard of Amantadine. This product is intended for research and analytical applications. Amantadine (1-Adamantanamine) is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine also has anti-orthopoxvirus and anticancer activity. Amantadine can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research [4] .
    Amantadine (Standard)
  • HY-W653905

    Isotope-Labeled Compounds Infection Neurological Disease Cancer
    Amantadine-d15 hydrochloride is deuterated labeled Amantadine. Amantadine (1-Adamantanamine) is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine also has anti-orthopoxvirus and anticancer activity. Amantadine can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research .
    Amantadine-d15 hydrochloride
  • HY-B0402A
    Amantadine hydrochloride
    4 Publications Verification

    1-Adamantanamine hydrochloride; 1-Adamantylamine hydrochloride; 1-Aminoadamantane hydrochloride

    Influenza Virus Orthopoxvirus SARS-CoV Apoptosis Bcl-2 Family CDK Infection Neurological Disease Cancer
    Amantadine (1-Adamantanamine) hydrochloride is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine hydrochloride inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine hydrochloride also has anti-orthopoxvirus and anticancer activity. Amantadine hydrochloride can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research .
    Amantadine hydrochloride
  • HY-B0402AR

    Influenza Virus Orthopoxvirus SARS-CoV Apoptosis Bcl-2 Family CDK Infection Neurological Disease Cancer
    Amantadine (hydrochloride) (Standard) is the analytical standard of Amantadine (hydrochloride). This product is intended for research and analytical applications. Amantadine (1-Adamantanamine) hydrochloride is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine hydrochloride inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine hydrochloride also has anti-orthopoxvirus and anticancer activity. Amantadine hydrochloride can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research .
    Amantadine (hydrochloride) (Standard)
  • HY-B0402
    Amantadine
    4 Publications Verification

    1-Adamantanamine; 1-Aminoadamantane

    Influenza Virus Orthopoxvirus SARS-CoV Apoptosis CDK Bcl-2 Family Infection Neurological Disease Cancer
    Amantadine (1-Adamantanamine) is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine also has anti-orthopoxvirus and anticancer activity. Amantadine can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research .
    Amantadine
  • HY-B0402B

    1-Adamantanamine sulfate; 1-Aminoadamantane sulfate

    Influenza Virus Orthopoxvirus SARS-CoV Apoptosis CDK Bcl-2 Family Infection Neurological Disease Cancer
    Amantadine (1-Adamantanamine) sulfate is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine sulfate inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine sulfate also has anti-orthopoxvirus and anticancer activity. Amantadine sulfate can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research .
    Amantadine sulfate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: